Centuple Global Chart
Centuple Global Share Key Metrics
Volume
15085.00
Market Cap
24.98 CR
LTQ@LTP
100@43.41
ATP
43.98
Var Margin
27.28 %
Circuit Range
43.41-47.97
Delivery %
94.11 %
Value
6.63 L
ASM/GSM
No
Market Lot
1
Summary
Centuple Global Fundamentals
View MoreP/E Ratio
0
P/B Ratio
0
Div. Yield
0
Sector P/E
42.2
Sector P/B
2.1
Sec. Div. Yield
79.54
Centuple Global Resistance and Support
Pivot 45.48
Resistance
First Resistance
46.94
Second Resistance
48.2
Third Resistance
49.66
Support
First Support
44.22
Second Support
42.76
Third Support
41.5
Centuple Global Corporate Actions
| Date | Agenda |
|---|---|
| 2026-03-18 | Others |
| 2026-02-25 | Others |
| 2026-01-28 | Quarterly Results |
| 2025-12-17 | Others |
| 2025-11-12 | Quarterly Results |
| 2025-10-06 | Others |
| 2025-09-24 | To consider issue of Warrants |
| 2025-09-10 | Preferential Issue of shares & Others |
| 2025-08-28 | Others |
| 2025-08-18 | Increase in Authorised Capital |
| 2025-08-06 | Quarterly Results |
| 2025-05-28 | Audited Results |
| 2025-04-30 | Others |
| 2025-04-15 | Others |
| 2025-04-04 | Others |
| 2025-03-06 | Others |
| 2025-02-12 | Quarterly Results |
| 2025-01-13 | Reduction of Capital |
Centuple Global News
About Centuple Global
NSE : 0
BSE : 531099
ISIN : INE396H01019
Rubra Medicaments Limited was incorporated on 27thSeptember 1991 as a Private Limited Company under theCompanies Act 1956 in the name of Rubra MedicamentsPrivate Limited. The Company was subsequently convertedinto a Public Limited Company and the name of the Companywas changed to Rubra Medicaments Limited with effect from2nd December 1994.The Company''s existing factory for manufacture ofpharmaceutical formulations is located at Plot.No.109/3IDA Phase-II Cherlapally R.R.District (A.P) with aninstalled capacity as under:Tablets - 339.60 lacs nos.Capsules - 90.00 lacs nos.The Company has started operations from March'' 1994 andpresently manufactures antimalarial antispasmodicantianelgesic antiasthamatic and antibiotics formulationsin tablets and capsule form.The Company also manufactures generic and calcium tablets.The Company now proposes to expand its existing capacityfor tablets and capsules and also manufacture AntiRheumatic Drug Analgesic and Antipyritic drugs Antipepticulcerant Drugs Antianthraitic (Tropical Cream)Anti-infective (Skin Preparation) Nutrition supplement(Aur. Iron preparation) formulations.
Centuple Global Management
| Name | Position |
|---|---|
| Shruti Gupta | Non Executive Independent Director |
| Shubham Chaudhary | Managing Director & Chief Financial Officer |
Centuple Global Similar Stocks
Devine Impex Ltd.
8.15
0.00 (0.00%)
Svarnim Trade Udyog Ltd.
10.08
-0.47 (4.45%)
Trio Mercantile & Trading Ltd.
1.09
0.00 (0.00%)
Shyama Computronics And Services Ltd.
2.93
0.00 (0.00%)
Vivanza Biosciences Ltd.
1.94
0.11 (6.01%)
Datiware Maritime Infra Ltd.
26.20
0.00 (0.00%)
Simplex Papers Ltd.
1573.00
0.00 (0.00%)
Flora Corporation Ltd.
8.15
0.35 (4.49%)
CHD Chemicals Ltd.
6.65
-0.41 (5.81%)
Centuple Global FAQs
